Oncolytics Biotech (ONCY) 1.01 $ONCY Oncolytics'

New Post Public Reply Private Reply Replies (0) Message Board

Mar 4, 2015 at 6:37 PM

Oncolytics Biotech (ONCY) 1.01 $ONCY

Oncolytics' Reolysin Gets Orphan Drug Status Yet Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 1:38PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for primary peritoneal cancer.
CYTK: 7.95 (-0.02), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02), THRX: 19.64 (+0.08)

Premarket Gainers / Losers as of 9:10 em
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST

BV: 6.41 (-2.67), AMRN: 1.69 (+0.15), PHMD: 1.98 (+0.15), BOBE: 46.36 (-13.28), NVGN: 3.36 (+0.85), EFUT: 4.70 (+0.57), TNET: 33.93 (-3.95), ATOS: 2.03 (+0.07), FAST: 39.82 (-1.28), W: 28.90 (+3.65), TIVO: 11.55 (+0.30), CYCC: 1.10 (-0.32), ANF: 20.27 (-3.72), CYTX: 1.14 (-0.06), AEO: 15.96 (+1.14), AMBA: 67.49 (+4.44), CRMD: 6.16 (+0.66), ONCY: 1.01 (-0.15), EXAS: 21.90 (+0.84), ATHM: 42.61 (+4.21), SOL: 1.43 (+0.08), VEEV: 25.72 (-6.97), OREX: 8.49 (+0.85), NURO: 1.78 (+0.03), ACHN: 11.63 (-0.51), CNDO: 3.23 (+0.44), SWHC: 14.34 (+1.29), IFON: 2.71 (+1.01)

Nasdaq stocks posting largest volume increases
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OREX: 8.49 (+0.85), GDEF: 10.38 (-0.02), WBB: 17.22 (-0.03), ONCY: 1.01 (-0.15), CYCC: 1.10 (-0.32), DRAM: 3.29 (+0.34), AXPW: 0.23 (-0.01), CMLS: 3.13 (-0.18), SQBK: 25.74 (+0.08), MITL: 9.56 (+0.20), TSRI: 5.07 (-0.21), MBLX: 0.97 (-0.08)

Most active Nasdaq-traded stocks
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.59 (-0.22), OREX: 8.49 (+0.85), MU: 29.26 (-0.40), ONCY: 1.01 (-0.15), FB: 80.89 (+1.29), ARCP: 10.10 (+0.02), ZNGA: 2.39 (+0.04), MSFT: 43.05 (-0.23), INTC: 34.12 (+0.02), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21)

Another Orphan Drug tag for Oncolytics' Reolysin
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:48AM CST

ONCY: 1.01 (-0.15)

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer
CNW Group - Tue Mar 03, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"

(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN(®), for the treatment of cancer of the fallopian tube. The designation was granted on the basis of the Company's December 2014 application for an Orphan Drug Designation encompassing ovarian, fallopian tube and primary peritoneal cancers which are generally treated as one indication. On February 11, 2015, the Company announced that it had received Orphan Drug Designation for ovarian cancer.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)

Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 19, 11:10AM CST
Oncolytics Biotech Inc. (ONCY) completed enrolment in a phase II study on its lead candidate, Reolysin, in patients suffering from advanced or metastatic colorectal cancer.
LCI: 62.28 (+0.01), ONCY: 1.01 (-0.15), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)

Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST

GENE: 5.75 (+0.39), HTBX: 6.45 (-0.18), SGNL: 2.89 (+0.20), ROSG: 3.35 (unch), TTPH: 38.50 (-0.82), ONCY: 1.01 (-0.15), CLRX: 1.27 (-0.05), MELA: 1.82 (-0.01), AKAO: 10.42 (-0.33), WGBS: 4.80 (-0.05), EGRX: 37.72 (+1.03)

Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 3:08PM CST
Oncolytics' (ONCY) lead candidate Reolysin gets orphan drug status for pancreatic cancer.
IPXL: 40.40 (+0.47), BMRN: 109.79 (+1.43), ONCY: 1.01 (-0.15), CBM: 33.97 (+0.02)

Oncolytics Bio completes enrollment in Canadian cancer trial
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 11:45AM CST

ONCY: 1.01 (-0.15)

Oncolytics Biotech® Inc. Announces Completion of Enrollment in Randomized Phase II Colorectal Cancer Study
CNW Group - Wed Feb 18, 5:30AM CST
Oncolytics Biotech(®) Inc. ("Oncolytics"

(TSX:ONC, NASDAQ:ONCY) today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN(® )in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.
ONCY: 1.01 (-0.15), ONC.TO: 1.26 (-0.18)

Oncolytics Bio's lead product an Orphan Drug for pancreatic cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 1:04PM CST

ONCY: 1.01 (-0.15)

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer
PR Newswire - Tue Feb 17, 5:30AM CST
Oncolytics Biotech® Inc. ("Oncolytics"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

PathoSearch: A New Era in Pathology With Visual Search

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

OneOdio Showcases Innovation at IFA 2026 in Berlin

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

PureHealth's Acid Reflux Solutions: An Investor's Insight

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

USPS Honors 150 Years of the U.S. Coast Guard Academy

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Delhi Pushes Innovation Against Dryland Challenges

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Silk Road Maritime Extends Its Global Reach in 2026

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...